Clinical Overview of Cytopenic Myelofibrosis and Pacritinib

Nov 10, 2022 12:00pm -
Nov 10, 2022 01:00pm

Event Description

Clinical Overview of Cytopenic Myelofibrosis and Pacritinib

This webinar is sponsored by:
CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European  Hematology Association (EHA) 2022 Congress

Date: Thursday, November 10, 2022
Time: 12:00pm EST

Patrick Tamburro, PharmD – Medical Science Liaison

Description: This webinar will provide a brief overview of Myelofibrosis pathophysiology and symptomology with a focus on cytopenias and their association with poor prognosis,
Pacritinib’s mechanism of action, efficacy as well as safety in clinical trials across all platelet counts, and compassionate use program outcomes. Indication and latest National Comprehensive Cancer Network (NCCN) guidelines will also be covered with time for questions at the end.

Learning Objectives:

  1. Recognize unmet needs for cytopenic myelofibrosis patients and poor prognosis associated with cytopenias
  2. Efficacy and Safety of pacritinib in clinical trials in patients with platelets counts below as well as above 50 × 109/L.
  3. Pacritinib’s indication
  4. Latest NCCN Guideline recommendations

Virtual Platform: GoToWebinar
Target Audience: Hematology/Oncology healthcare providers (MD,DO, PA, NP, RN)

Fee: $0
CME/CE: 0 hrs

IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder.

Event Type:Webinar
Early registration ends on Sep 01, 2022.
Regular registration starts on Sep 02, 2022 and ends on Nov 09, 2022.
Late registration starts on Nov 10, 2022.